KZR vs NDAQ · $53.9M cap vs P/E 41, rev $2.53B
Kezar Life Sciences Inc (KZR) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Kezar Life Sciences Inc (KZR) is a biotechnology company listed on NASDAQ.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported KZR revenue for 2024-12-31 was $0. Net income was -$83.7M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. KZR currently screens at market cap $53.9M.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
KZR currently screens at market cap $53.9M. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the KZR and NDAQ stock pages for the full models.
Not investment advice.